Shares of Mesa Laboratories, Inc. (NASDAQ:MLAB) have received an average broker rating score of 1.00 (Strong Buy) from the one analysts that cover the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a strong buy recommendation.
Analysts have set a one year consensus price target of $255.00 for the company and are predicting that the company will post $2.13 EPS for the current quarter, according to Zacks. Zacks has also given Mesa Laboratories an industry rank of 99 out of 256 based on the ratings given to related companies.
Several equities analysts recently commented on MLAB shares. Zacks Investment Research raised shares of Mesa Laboratories from a “hold” rating to a “buy” rating and set a $256.00 price objective for the company in a research note on Wednesday, April 3rd. ValuEngine downgraded shares of Mesa Laboratories from a “buy” rating to a “hold” rating in a research note on Tuesday, April 23rd. Sidoti started coverage on shares of Mesa Laboratories in a research note on Wednesday, March 13th. They issued a “neutral” rating for the company. BidaskClub downgraded shares of Mesa Laboratories from a “buy” rating to a “hold” rating in a research note on Thursday, March 7th. Finally, TheStreet raised shares of Mesa Laboratories from a “c” rating to a “b-” rating in a research note on Friday, February 8th.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 14th. Investors of record on Friday, May 31st will be paid a $0.16 dividend. This represents a $0.64 annualized dividend and a yield of 0.33%. The ex-dividend date is Thursday, May 30th. Mesa Laboratories’s payout ratio is 10.36%.
In related news, Director David M. Kelly sold 684 shares of the stock in a transaction that occurred on Tuesday, March 19th. The shares were sold at an average price of $230.00, for a total value of $157,320.00. Following the completion of the transaction, the director now owns 3,584 shares of the company’s stock, valued at approximately $824,320. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. 15.00% of the stock is owned by corporate insiders.
A number of large investors have recently modified their holdings of the stock. Altshuler Shaham Ltd bought a new position in shares of Mesa Laboratories during the first quarter valued at $27,000. Bronfman E.L. Rothschild L.P. bought a new position in shares of Mesa Laboratories during the fourth quarter valued at $34,000. O Shaughnessy Asset Management LLC bought a new position in shares of Mesa Laboratories during the first quarter valued at $41,000. Huntington National Bank bought a new position in shares of Mesa Laboratories during the fourth quarter valued at $52,000. Finally, One Wealth Advisors LLC bought a new position in shares of Mesa Laboratories during the first quarter valued at $72,000. 73.23% of the stock is owned by institutional investors and hedge funds.
About Mesa Laboratories
Mesa Laboratories, Inc designs, manufactures, and markets quality control instruments and disposable products. The company's Instruments segment offers data loggers, which are precision instruments used in critical manufacturing, quality control, and validation applications; medical meters and calibration solutions used to test various parameters of the dialysis fluid, and the calibration and operation of the dialysis machine; gas flow calibration and air sampling equipment that are used for industrial hygiene assessments, calibration of gas metering equipment, and environmental air monitoring; and torque testing systems used for measure bottle cap tightness.
Further Reading: How prevalent are 12b-1 fees?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mesa Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesa Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.